CANY
AMRX icon

Caxton Associates (New York)’s Amneal Pharmaceuticals AMRX Stock Holding History

Caxton Associates (New York)’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-29,150
Closed -$243K – 489
2024
Q3 		$243K Buy
+29,150
New +$228K 0.01% 465
2024
Q2 		– Sell
-91,481
Closed -$554K – 469
2024
Q1 		$554K Buy
91,481
+8,088
+10% +$45.6K 0.04% 307
2023
Q4 		$506K Sell
83,393
-36,887
-31% -$164K 0.03% 320
2023
Q3 		$508K Buy
+120,280
New +$449K 0.07% 239

Other funds holding AMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $1.6B AUM 121.58% 1-Year Est. Return